These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9629873)

  • 1. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
    Hesketh PJ; Gralla RJ; du Bois A; Tonato M
    Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
    Grunberg SM; Osoba D; Hesketh PJ; Gralla RJ; Borjeson S; Rapoport BL; du Bois A; Tonato M
    Support Care Cancer; 2005 Feb; 13(2):80-4. PubMed ID: 15599601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methodology of the evaluation of antiemetics].
    Bergmann JF
    Bull Cancer; 1995 Dec; 82(12):1062-6. PubMed ID: 8745674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control.
    Schnell FM
    Oncologist; 2003; 8(2):187-98. PubMed ID: 12697943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed emesis following anticancer chemotherapy.
    Kris MG; Roila F; De Mulder PH; Marty M
    Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of antiemetic drugs.
    Jordan K; Schmoll HJ; Aapro MS
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.
    Hesketh PJ
    Oncologist; 1999; 4(3):191-6. PubMed ID: 10394587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal for classifying the acute emetogenicity of cancer chemotherapy.
    Hesketh PJ; Kris MG; Grunberg SM; Beck T; Hainsworth JD; Harker G; Aapro MS; Gandara D; Lindley CM
    J Clin Oncol; 1997 Jan; 15(1):103-9. PubMed ID: 8996130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The control of chemotherapy-induced nausea and vomiting].
    Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
    Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.